| DC48807 |
L-Aspartic acid-1,4-13C2 |
L-Aspartic acid-1,4-13C2 is the 13C-labeled L-Aspartic acid. L-Aspartic acid is is an amino acid, shown to be a suitable prodrug for colon-specific drug deliverly. |
|
| DC48808 |
L-Alanine-1-13C,15N |
L-Alanine-1-13C,15N (L-2-Aminopropionic acid-1-13C,15N) is the 13C- and 15N-labeled L-Alanine. L-Alanine is a non-essential amino acid, involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and central nervous system. |
|
| DC48809 |
L-Serine1-13C,15N |
L-Serine1-13C,15N ((-)-Serine-13C,15N) is the 13C- and 15N-labeled L-Serine. L-Serine ((-)-Serine; (S)-Serine), one of the so-called non-essential amino acids, plays a central role in cellular proliferation. |
|
| DC48810 |
DL-Alanine-1-13C |
DL-Alanine-1-13C is the 13C-labeled DL-Alanine. DL-alanine, an amino acid, is the racemic compound of L- and D-alanine. DL-alanine is employed both as a reducing and a capping agent, used with silver nitrate aqueous solutions for the production of nanoparticles. DL-alanine can be used for the research of transition metals chelation, such as Cu(II), Zn(II), Cd(11). DL-alanine, a sweetener, is classed together with glycine, and sodium saccharin. DL-alanine plays a key role in the glucose-alanine cycle between tissues and liver. |
|
| DC48811 |
DL-Alanine-3-13C |
DL-Alanine-3-13C is the 13C-labeled DL-Alanine. DL-alanine, an amino acid, is the racemic compound of L- and D-alanine. DL-alanine is employed both as a reducing and a capping agent, used with silver nitrate aqueous solutions for the production of nanoparticles. DL-alanine can be used for the research of transition metals chelation, such as Cu(II), Zn(II), Cd(11). DL-alanine, a sweetener, is classed together with glycine, and sodium saccharin. DL-alanine plays a key role in the glucose-alanine cycle between tissues and liver. |
|
| DC48812 |
L-Alanine-2-13C |
L-Alanine-2-13C (L-2-Aminopropionic acid-2-13C) is the 13C-labeled L-Alanine. L-Alanine is a non-essential amino acid, involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and central nervous system. |
|
| DC48813 |
L-Alanine-3-13C |
L-Alanine-3-13C (L-2-Aminopropionic acid-3-13C) is the 13C-labeled L-Alanine. L-Alanine is a non-essential amino acid, involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and central nervous system. |
|
| DC48814 |
L-Cysteine-3-13C |
L-Cysteine-3-13C is the 13C-labeled L-Cysteine. L-Cysteine is a conditionally essential amino acid, which acts as a precursor for biologically active molecules such as hydrogen sulphide (H2S), glutathione and taurine. L-Cysteine suppresses ghrelin and reduces appetite in rodents and humans. |
|
| DC48815 |
L-Cysteine-1-13C |
L-Cysteine-1-13C is the 13C-labeled L-Cysteine. L-Cysteine is a conditionally essential amino acid, which acts as a precursor for biologically active molecules such as hydrogen sulphide (H2S), glutathione and taurine. L-Cysteine suppresses ghrelin and reduces appetite in rodents and humans. |
|
| DC48816 |
L-Serine-2-13C |
L-Serine-2-13C ((-)-Serine-2-13C) is the 13C-labeled L-Serine. L-Serine ((-)-Serine; (S)-Serine), one of the so-called non-essential amino acids, plays a central role in cellular proliferation. |
|
| DC48817 |
L-Serine-13C |
L-Serine-13C ((-)-Serine-13C) is the 13C-labeled L-Serine. L-Serine ((-)-Serine; (S)-Serine), one of the so-called non-essential amino acids, plays a central role in cellular proliferation. |
|
| DC48820 |
hDHODH-IN-8
Featured
|
hDHODH-IN-8 is a potent inhibitor of human dihydroorotate dehydrogenase (hDHODH) with an IC50 of 16 nM. hDHODH-IN-8 has potent antiproliferative activity and excellent aqueous solubility. hDHODH-IN-8 has the potential for the research of tumor disease, especially lymphoma. |
|
| DC48824 |
ME-143 |
ME-143 is a second-generation tumor-specific inhibitor of NADH oxidase. ME-143 inhibits the WNT/β-catenin pathway in colorectal cancer cells. ME-143 has broadly active against cancers in vitro and in vivo. |
|
| DC48828 |
1-Methoxyphaseollidin |
1-Methoxyphaseollidin, a flavonoid compound, is a lysoPAF acetyltransferase inhibitor, with an IC50 of 48 μM. 1-Methoxyphaseollidin exhibits anti-H.pylori activity against the CLAR and AMOX-resistant strain as well as four CLAR (AMOX)-sensitive strains. |
|
| DC48832 |
MAO A/HDAC-IN-1 |
MAO A/HDAC-IN-1 is a dual inhibitor of monoamine oxidase A (MAO A) and HDAC. MAO A/HDAC-IN-1 can be used for glioma research. |
|
| DC48845 |
NADP sodium hydrate |
NADP sodium hydrate, a β-Nicotinamide adenine dinucleotide phosphate sodium salt, is a redox cofactor. NADP sodium hydrate is a key cofactor for electron transfer in the metabolism, being alternately oxidized (NADP+) and reduced (NADPH). |
|
| DC48846 |
21-Deoxycortisol |
21-Deoxycortisol is an endogenous metabolite. 21-Deoxycortisol is a sign of congenital adrenal hyperplasia. |
|
| DC48847 |
EB-0156 |
EB-0156 is a potent inhibitor of ER α-glucosidases (α-Glu) Iand II with IC50s of 0.0479 and less than 0.001 μM, respectively. EB-0156 is a N-substituted derivative of valiolamine with broad-spectrum antiviral. EB-0156 has the potential for the reseach of broad-spectrum agent against the existing and emerging viruses. |
|
| DC48850 |
Mycestericin G |
Mycestericin G is a sphingosine-like fungal metabolite that exhibits immunosuppressive activity. |
|
| DC48856 |
Fellutanine A |
Fellutanine A, a diketopiperazine alkaloid, is a fungal metabolite from cultures of Penicillium fellutanum. |
|
| DC48871 |
Enpp-1-IN-6 |
Enpp-1-IN-6 is a potent inhibitor of ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1). The ENPP 1 has broad specificity and can cleave a variety of substrates, including phosphodiester bonds of nucleotides and nucleotide sugars and pyrophosphate bonds nucleotides and nucleotide sugars. Enpp-1-IN-6 has the potential for the research of cancer and infectious diseases (extracted from patent WO2021203772A1, compound 51). |
|
| DC48876 |
Protectin D1 |
Protectin D1, neuroprotectin D1 when generated by neural cells, is a member of a new family of bioactive products generated from docosahexaenoic acid. Protectin D1 is also a specialized pro-resolving mediator with potent pro-resolving and anti-inflammatory effects in vivo in several human disease models. |
|
| DC48891 |
Isokotanin B |
Isokotanin B is a metabolite of bicoumarin isolated from the sclerotia of Aspergillus alliaceus. Isokotanin B shows activity against the corn earworm Helicoverpa zea and the dried fruit bettle Carpophilus hemipterus. |
|
| DC48893 |
SGK1-IN-4
Featured
|
SGK1-IN-4 (compound 17a) is a highly selective, orally active SGK1 inhibitor. SGK1-IN-4 can be used for osteoarthritis research. |
|
| DC48903 |
Dual AChE-MAO B-IN-1 |
Dual AChE-MAO B-IN-1 (compound 15) is an orally bioavailable CNS-permeant potent inhibitor of both human AChE (IC50=550 nM) and MAO B (IC50=8.2 nM). Dual AChE-MAO B-IN-1 behaves as a safe and metabolically stable neuroprotective agent, devoid of cytochrome liability. |
|
| DC48911 |
CFM 1571 hydrochloride |
CFM 1571 hydrochloride is the stimulator of the nitric oxide receptor, soluble guanylate cyclase (sGC) with an EC50 and IC50 of 5.49 μM and 2.84 μM, respectively. Soluble guanylate cyclase (sGC) is a key signal-transduction enzyme activated by nitric oxide (NO). CFM 1571 (hydrochloride) (compound 32) has the potential for the research of cardiovascular and other diseases. |
|
| DC48917 |
EB-0176 |
EB-0176 is a potent inhibitor of ER α-glucosidases (α-Glu) Iand II with IC50s of 0.6439 and 0.0011 μM, respectively. EB-0176 is a N-substituted derivative of valiolamine with broad-spectrum antiviral. EB-0176 has the potential for the reseach of broad-spectrum agent against the existing and emerging viruses. |
|
| DC48922 |
GSK2647544 |
GSK2647544 is an orally available, selective inhibitor of Lp-PLA2. Lipoprotein-associated phospholipase (Lp-PLA2) is a calcium-independent phospholipase A2 with proinflammatory activities that is primarily secreted by monocyte-derived macrophages. |
|
| DC48927 |
Hcyb1 |
Hcyb1 is a highly selective PDE2 inhibitor. Hcyb1 has a highly selective inhibition of PDE2A (IC50=0.57 μM) and over 250-fold selectivity against other recombinant PDE family members. Hcyb1 produces neuroprotective and antidepressant‐like effects most likely mediated by cAMP/cGMP-CREB-BDNF signaling. |
|
| DC48930 |
Fumiquinazoline D |
Fumiquinazoline D, a secondary metabolite, is a mycotoxin. |
|
